CSF1R macrophage/monocyte signaling in MPN
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-15 — Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML): Phase I/II trial combines axatilimab (anti-CSF1R mAb) with ruxolitinib in MF and CMML, testing whether dual macrophage/monocyte + JAK-STAT blockade is tolerable and clinically active; dose-finding stage with no efficacy data yet. (novelty: 3)
Open questions
Related
Contributing findings
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
15-jul-2026
novelty 3
per-area 4
introduces